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Abstract
Nicotine leads to both activation and desensitization (inactivation) of nicotinic acetylcholine receptors (nAChRs). This study
tested the hypothesis that nicotine and a selective antagonist of b2*nAChRs would have similar effects on affective
behavior. Adult C57BL/6J male mice were tested in a conditioned emotional response (CER) assay which evaluates the
ability of an aversive stimulus to inhibit goal-directed behavior. Mice lever-pressed for a saccharin reinforcer according to a
variable schedule of reinforcement during sessions in which two presentations of a compound light/tone conditioned
stimulus (CS) co-terminated with a 0.1 or 0.3 mA, 0.5 s footshock unconditioned stimulus (US). During testing in the
absence of the US, mice received doses of i.p. nicotine (0, 0.0032, 0.01, 0.032, 0.1 mg/kg) or a selective b2 subunit containing
nAChR (b2*nAChR) antagonist dihydro-beta-erythroidine (0, 0.1, 0.3, 1.0, 3.0 mg/kg DHbE). There was a dose-dependent
effect of nicotine revealing that only low doses (0.01, 0.032 mg/kg) increased CER suppression ratios (SR) in these mice.
DHbE also dose-dependently increased SR at the 3 mg/kg dose. In ethological measures of fear2/anxiety-like behavior,
these doses of nicotine and DHbE significantly reduced digging behavior in a marble burying task and 0.3 mg/kg DHbE
promoted open-arm activity in the elevated plus maze. Doses of nicotine and DHbE that altered affective behavior had no
effect on locomotor activity. Similar to previous reports with anxiolytic drugs, low dose nicotine and DHbE reversed SR in a
CER assay, decreased digging in a marble burying assay and increased open arm activity in the elevated plus maze. This
study provides evidence that inactivation of b2*nAChRs reduces fear-like and anxiety-like behavior in rodents and suggests
that smokers may be motivated to smoke in part to desensitize their b2*nAChRs. These data further identify b2*nAChR
antagonism as a potential therapeutic strategy for relief of negative affect and anxiety.
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Introduction
Human and animal studies indicate that nicotine exerts its
psychoactive effects by binding to nicotinic acetylcholine receptors
(nAChRs) in the brain [1,2]. nAChRs comprised of the b2 subunit
(b2*nAChRs; *denotes assembly with other subunits) have high
binding affinity for nicotine and the endogenous neurotransmitter,
acetylcholine (ACh) [3–6]. b2*nAChRs are enriched on neurons
in limbic system brain areas that regulate both affect and reward
[3,6–16] suggesting that these nAChR subtypes may serve a dual
role in supporting reward-like behavior and relieving negative
affect. nAChRs are ion channels that can be activated as well as
desensitized (inactivated) by nicotine [17–20]. A preponderance of
the evidence suggests that activation of b2*nAChRs supports
nicotine conditioned place preference and nicotine self-adminis-
tration, models of nicotine reward and reinforcement [21–32] (but
see [33]). These studies used a conditioned emotional response
(CER) assay, a marble burying task and an elevated plus maze
experiment to test the hypothesis that inactivation of b2*nAChRs
attenuates fear and anxiety-like behavior in mice.
CER is an appetitive, operant task in which lever pressing
maintained by a positive reinforcer (saccharin solution) is
interrupted by presentation of a conditioned stimulus (CS, light
and tone) that co-terminates with an aversive unconditioned
stimulus (US, 0.1 or 0.3 mA, 0.5 s mild footshock). This study
tested if nicotine and a selective antagonist of b2*nAChRs,
dihydro-beta-erythroidine (DHbE), would attenuate conditioned
suppression of responding in the presence of an aversive CS in the
absence of footshock. During CER, subjects serve as their own
controls within sessions to return a suppression ratio (SR) score =
A/(A+B) where A is lever pressing during the 60 s CS period and
B is lever pressing during the 60 s prior to CS presentation (Pre-
CS). An SR < 0 is indicative of conditioned suppression whereas
SR < 0.5 indicates that rodent responding is unaffected by
presentation of the CS. The CER assay has good face validity for
tobacco users who experience stressors during goal-oriented
behavior on a daily basis. Separate groups of mice were tested
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using an ethological marble burying task where increased digging,
rather than suppression of activity, is thought to be interpretive of
negative affective behavior, and in an elevated plus maze assay
where increased activity in the open arms, relative to the enclosed
arms of the maze, is thought to reflect anxiolysis-like behavior. As
a follow-up to experiments that evaluated affective-like phenotype,
a locomotor activity assay using a beam-break apparatus
confirmed that doses of nicotine and DHbE in these experiments
did not affect locomotor activity.
Materials and Methods
Subjects
Twenty nine C57BL/6J, adult, male mice from Jackson Labs
(Bar Harbor, ME) or derived in a Virginia Commonwealth
University (VCU) breeding colony were used in these studies. Mice
had ad libitum access to both food and water in their home cages.
Animals were group-housed (2–5 per cage) with 1/8 inch corn cob
bedding in a vivarium with a 12 h light/dark cycle (lights on
0600). Mice were habituated to the test room and experimenter
handling for 3 days prior to any training or testing.
Ethics Statement
Efforts were made to minimize mouse discomfort in these
experiments. Mild footshock without analgesia and experimenter
injections were necessary to perform these studies that model
affective-like behavior in mice. Experiments were approved by the
VCU Institutional Animal Care and Use Committee (Protocol
Number: AM-10163) and were in compliance with the Guide for
Care and Use of Laboratory Animals (Institute of Laboratory Animal
Resources, 2010).
Apparatus
CER experiments were conducted in mouse operant chambers
(21.6 cm617.8 cm612.7 cm; Med Associates, St. Albans, VT).
An LED cue light with an opaque cover was positioned 5.5 cm
above the operant lever with a liquid dipper receptacle centered
on the same wall. A speaker and a 2.24 watt incandescent house-
light were positioned 9.5 cm from the floor on the opposite wall of
the operant chamber. The floor consisted of steel rods (0.32 cm in
diameter placed 0.79 cm apart) connected to a Med Associates
shock generator/scrambler. All data were collected via Med PC
software. Marble burying took place in a polycarbonate cage
(33 cm621 cm69 cm high) filled with 5 cm of loose wood chip
bedding (Harlan Sani-Chip, Indianapolis, IN). The elevated plus
maze was constructed of wood with white laminated flooring on
two (5630 cm) open arms that were perpendicular to two
equivalent, white, laminated, enclosed arms with 15.25 cm black
Plexiglass wall enclosures. The entire apparatus was elevated
68 cm above the floor. Experimentation took place under
fluorescent light illumination. A ceiling-mounted camera was
interfaced to a PC for collection of data using ANY-maze tracking
software by Stoelting (Wood Dale, IL). Locomotor testing was
conducted in two adjoining chambers (measuring
26.5 cm612.7 cm626.2 cm and 16.8 cm612.7 cm612.7 cm). A
locomotor unit was defined as the breaking of two adjacent light
beams (3 cm apart). Illumination was provided by a single 23 watt
fluorescent light bulb. Data was collected using Med Associates
software. All experimental chambers were cleaned between
animals with 2% Nolvosan (Pfizer Animal Health, Madison, NJ).
Drugs
Nicotine hydrogen tartrate (Sigma Aldrich, St. Louis, MO) was
dissolved in 0.9% sterile saline with pH adjusted to 7.1–7.3. DHbE
(Sigma Aldrich, St. Louis, MO) was dissolved in 0.9% sterile
saline. Nicotine doses are expressed as freebase and DHbE doses
are expressed as hydrogen bromide salt. As with previous nicotine
place conditioning studies [28,34], injections were delivered i.p. in
volumes of 0.1 ml/30 g. Nicotine was administered immediately
prior to CER, marble burying and locomotor tests. After DHbE
injection, animals were returned to their home cages for 15
minutes before CER, elevated plus maze and locomotor testing
and for 30 minutes prior to the marble burying task. Weights were
measured approximately 1 h prior to behavioral assays.
Behavioral Procedures
Conditioned emotional response (CER). The CER para-
digm consisted of several phases of operant and Pavlovian training
followed by drug testing sessions where operant responding was
tested in the presence of a footshock-paired CS but in the absence
of the US footshock (Figure 1).
Magazine training. Subjects received eighty presentations of
10 mMol saccharin solution according to a variable interval 30
second (VI-30 s) schedule. Mice met criteria when they entered
the magazine for 20% of the dipper presentations. Animals failing
to meet this criteria were given a second, and if necessary, a third
exposure to magazine training before moving on to acquisition of
operant responding during overnight sessions.
CER acquisition of lever-pressing behavior. Mice were
trained to lever press for 0.01 ml of 10 mMol saccharin solution
delivered via liquid dipper during a single 16 hour overnight
session (adapted from [35]). Responding for saccharin reinforce-
ment was maintained on increasing fixed ratio (FR) schedules, FR
1 up to 10 reinforcers, FR 2 up to the subsequent 10 reinforcers
and FR 4 for the subsequent 20 reinforcers. This was followed by a
variable ratio (VR) 5 or variable interval (VI) 15 second schedule
of reinforcement until the end of the session. Mice were next
trained to lever press during 30 minute daily sessions (1400–
1800 h) for a saccharin reinforcer at the assigned variable schedule
of reinforcement for which they were trained. Mice meeting a
criterion of 10 reinforcers and 40 lever presses in a single session
advanced to CER training. The house light was on during all
acquisition and CER procedures in the absence of the CS.
CER training (operant responding with pavlovian CS + US
footshock conditioning). During 30 minute CER sessions,
saccharin continued to be available according to the variable
schedule of reinforcement presented during acquisition. Pseudo-
random presentation of two 60 s, compound CSs (house light off +
cue light on +70 dB, 2000 Hz tone) co-terminated with a 0.5 s,
0.3 mA footshock US. A second cohort of animals received all the
same conditions but was administered a 0.1 mA footshock US
shown previously to not affect suppression ratios [36]. The first CS
presentation occurred between min 3 and 12 and the second CS
between min 18 and 27. The number of lever presses were
recorded both for the 60 s Pre-CS period, immediately preceding
the onset of the CS, as well as during the CS. The suppression
ratio was calculated using the equation A/(A+B), where A is the
number of responses during the CS and B equals lever presses
during the Pre-CS period [37]. A suppression ratio of 0.5 indicates
no suppression of responding during the CS and a suppression
ratio of 0 reflects total suppression of responding during the CS.
All active lever-pressing in the absence of the CS was also
evaluated (NON-CS). Increases in suppression ratio following drug
treatment were interpreted as anxiolytic-like behavior. Once stable
baseline responding and suppression ratios (#0.1 for the 0.3 mA
condition) were established for 3 consecutive days, mice proceeded
to drug testing.
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CER drug testing. Drug testing took place in the absence of
footshock US using a within-subject Latin square design. Animals
received 0, 0.0032, 0.01, 0.032 or 0.1 mg/kg i.p. nicotine or 0, 0.1,
0.3, 1 or 3 mg/kg i.p. DHbE before CER. At least 2 days of CER
training were administered between doses to allow for wash-out of
drug. These intermediate training sessions further assured that
responding returned to baseline between doses of drug.
Marble burying. Using a within-subject, Latin Square
design, separate groups of mice received 0, 0.01 and 0.032 mg/
kg i.p. nicotine or 0 and 3 mg/kg i.p. DHbE. Marble burying
sessions were separated by at least 5 days as has been
demonstrated to provide a steady level of digging behavior in
the absence of treatment [38,39]. Prior to each test, 20 green, glass
marbles (10 mm diameter) were evenly arranged in a 465 grid on
sawdust bedding. Individual mice were placed into the side of the
experimental cage so as to not disturb any of the marbles. At the
conclusion of the 15 minute test, mice were returned to the home
cage; marbles at least 50% covered by the bedding were counted
as buried.
Elevated plus maze. Using a between-subject design, mice
receiving 0, 0.03 or 3 mg/kg i.p. DHbE were returned to their
home cage for a 15 min wait period and subsequently placed on
the center of an elevated plus maze apparatus (n = 9211 per dose).
Behavior was evaluated for a period of 10 minutes. Subjects were
scored for open arm entries, time spent in the open arms and
latency to explore the terminal zones (the extreme 5 cm) of the
open arms.
Locomotor test. Using a between-subject design, animals
received nicotine (0, 0.01 or 0.032 mg/kg i.p.) immediately prior
to placement into the small chamber of the Med Associates
apparatus. The door separating the two chambers was opened,
allowing animals free mobility throughout the apparatus. Breaking
of two adjacent beams (3 cm equidistant apart) constituted a
locomotor activity count. Behavior was assessed for ten minutes.
Mice that received DHbE (0, 0.3 or 3 mg/kg i.p.) were placed in
their home cages for 15 min following injections with the other
locomotor procedures as described for nicotine subjects.
Statistical Analysis
For CER experiments, repeated measures ANOVA assessed the
effect of nicotine and DHbE on suppression ratio, lever presses/
minute during the CS period, the Pre-CS period and the NON-CS
period. Paired t-tests were used as post hoc tests where appropriate.
Student’s t-test was used to assess the effect of footshock intensity
on suppression ratios. Repeated measures ANOVA and paired t-
tests were used to evaluate the effect of nicotine and DHbE on
number of marbles buried. ANOVA tests assessed elevated plus
maze activity as measured by open arm entries, time on the open
arms and latency to reach the end terminus of the open arms. Post
hoc t-tests and planned comparisons were performed between
vehicle- and drug-injected subjects. One-way ANOVA tested the
effects of drug doses on locomotor activity. Confidence intervals of
p,0.05 were reported as significant.
Results
On the 3 days of CER training prior to CER testing, NON-CS
responding was stable (F ,1) and suppression ratios were
consistently lower than 0.1 for mice trained to a 0.3 mA footshock.
The suppression ratios for mice receiving 0.1 mA footshock US
were significantly higher than mice exposed to 0.3 mA footshock
US following saline injection (0.1 mA=0.6960.15;
0.3 mA=0.0360.02; t14 = 5.691, p,0.001). In contrast to mice
that received a 0.3 mA footshock, mice trained with a 0.1 mA
footshock did not show a suppression of responding during the CS,
indicating that this suppression of behavior in 0.3 mA-trained
mice was a conditioned response to an aversive CS and not due to
a more generalized orienting response to the compound stimulus
CS used in these experiments. There was no effect of footshock
intensity on overall NON-CS or Pre-CS lever pressing (F’s ,1).
Figure S1 shows average lever presses per minute during the entire
30 minute sessions. Administration of nicotine resulted in a dose-
dependent increase in suppression ratio (F4,9 = 3.101, p,0.05) for
mice exposed to the 0.3 mA US. Post hoc t-tests revealed that low
doses of nicotine (0.01 and 0.032 mg/kg) significantly reversed
conditioned suppression of responding in comparison to when
animals received saline (t9 = 2.663 and 2.331, p’s ,0.05; Fig. 2A).
Despite consistent trends for elevated responding at doses of
nicotine that reversed conditioned suppression, raw scores for CS
lever pressing failed to reach significance following nicotine
injection (F4,9 = 0.867, p.0.05; Table 1). Unlike suppression
ratios, there was no effect of drug treatment on Pre-CS responding
(F4,9 = 1.771, p.0.05). There was an effect of nicotine treatment
observed for NON-CS responding, however (F4,9 = 9.832,
p,0.001). Post hoc tests showed that NON-CS lever pressing was
elevated in mice following 0.0032 mg/kg (t9 = 3.820, p,0.01),
0.032 mg/kg (t9 = 4.941, p,0.001) and 0.1 mg/kg (t9 = 2.483,
p,0.05) compared to treatment with saline (Table 2). It is possible
that nicotine was enhancing the reinforcing efficacy of the
saccharin stimulus as has been observed for a visual cue [40,41].
Further analysis comparing mice against their responding prior to
any injections indicated that this may have been due in part to
Figure 1. CER training and drug testing schedule. To introduce mice to the location of saccharin delivery, magazine training (Phase I) occurred
over days 1–3. CER acquisition of lever pressing maintained by 10 mMol saccharin solution took place during overnight sessions with increasingly
demanding schedules of reinforcement (Phase II; days 4–9) until mice reached criteria of 70 reinforcers and 100 s of correct magazine entries in a
session. This was followed by daily 30 minute sessions (Phase III) where mice lever pressing was maintained by saccharin under a variable schedule of
reinforcement. Mice moved onto the next Phase of training when they reached criteria of 40 lever presses and 10 reinforcers during a single 30
minute session (days 10–13). During CER training mice continued operant training but also received 2 explicit pairings of a light and tone conditioned
stimulus (CS) which co-terminated with a 0.1 or 0.3 mA footshock unconditioned stimulus (US) (Phase IV; days 14–43). Phase IV continued until all
mice showed a stable level of CS and NON-CS responding over 3 days. Drug testing (Phase V) consisted of lever pressing maintained by saccharin in
the presence of the CS but in the absence of the US. For these studies that used a within-subject, Latin square design, there were at least 2 CER
training days in between drug testing sessions to assure that mice returned to baseline prior to the next injection of drug.
doi:10.1371/journal.pone.0048665.g001
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anxiolytic effects of nicotine as well. Compared to days when they
had received no injection, there was a significant decrease in
NON-CS responding of mice following saline injection (t9 = 4.683,
p,0.001), suggesting that the stress of injection led to an overall
reduction in lever pressing activity (Table 2). Nicotine injection
appeared to reverse this effect; low doses of nicotine (0.01 and
0.032 mg/kg i.p.) that elevated suppression ratio responding
resulted in NON-CS lever pressing that did not differ from pre-
injection responding. A rewarding-like dose of nicotine (0.1 mg/kg
i.p.) [27,28,34] resulted in a similar elevation of responding
compared to saline injection, however, there were also significantly
fewer lever presses during the NON-CS compared to when no
injection was given, suggesting that this dose was not effective at
reversing suppression of overall responding that was stimulated by
the stress of injection.
In mice exposed to the 0.1 mA footshock US, administration of
nicotine did not significantly affect suppression ratios (F4,5 = 1.991,
p.0.05; Fig. 2C), CS responding (F4,5 = 0.103, p.0.05), Pre-CS
responding (F4,5 = 2.245, p.0.05; Table 1) or NON-CS respond-
ing (F4,5 = 1.46, p.0.05; Table 2).
A dose-dependent reversal of conditioned suppression was also
observed following treatment with the selective b2*nAChR
antagonist DHbE (F4,6 = 2.934, p,0.05). Compared to when they
received saline, mice showed a significant increase in suppression
ratios following injection of 3 mg/kg i.p. DHbE (t6 = 2.614,
p,0.05; Fig. 2B) suggesting that antagonism of the b2*nAChRs,
like low dose nicotine, reverses conditioned inhibition of behavior
in this task. Pre-treatment with DHbE resulted in a dose-
dependent increase in total lever pressing in the presence of the
CS (F4,6 = 3.338, p,0.05) reflecting a trend for elevated respond-
ing during the CS after administration of 3 mg/kg i.p. DHbE
compared to saline (t9 = 2.049, p=0.086; Table 1). As observed
during the nicotine treatment regimen above, Pre-CS responding
was not significantly affected by DHbE exposure (F4,6 = 1.382,
p.0.05; Table 1), but total NON CS lever pressing was reduced in
mice following saline injection compared to the training session
that immediately preceded the drug testing phase for DHbE
(t6 = 3.113, p,0.05; Table 2). Unlike nicotine, DHbE did not
significantly affect responding in the absence of the CS (Table 2).
Similarly to nicotine, mice trained with 0.1 mA US footshock
showed no effects of i.p. DHbE on suppression ratios (F4,5 = 1.263,
p.0.05; Fig. 2D), CS lever pressing (F4,5 = 1.334, p.0.05), Pre-CS
responding (F4,5 = 2.274, p.0.05; Table 1) or NON-CS respond-
ing (F4,5 = 1.112, p.0.05; Table 2). As observed with 0.3 mA-
trained mice, NON-CS responding was lower in mice following
saline injection compared to responding during training sessions
immediately prior to DHbE drug testing (t5 = 3.451, p,0.05;
Table 2), suggesting that the stress of injection may have led to a
suppression of overall lever-pressing activity.
A separate group of mice were tested in a marble burying task,
an ethological measure of digging behavior that is thought to
reflect changes in rodent affect [38,42–50]. Doses of i.p. nicotine
Figure 2. Low dose nicotine and the b2*nAChR antagonist DHbE reverse conditioned suppression. In mice trained to a 0.3 mA
unconditioned stimulus footshock during CER training, A) administration of nicotine resulted in a dose-dependent reversal of conditioned
suppression as measured by increased suppression ratios (F4,9 = 3.101, p,0.05; n = 10). B) The b2*nAChR antagonist DHbE also resulted in a significant
increase in suppression ratios in these mice (F4,6 = 2.934, p,0.05; n = 7), suggesting that inhibition of b2*nAChRs supports anxiolytic-like behavior in
the CER assay. C, D) Neither nicotine (F4,5 = 1.991, p.0.05; n = 6) nor DHbE (F4,5 = 1.263, p.0.05; n = 6) resulted in significant changes in suppression
ratio responding in mice exposed to 0.1 mA US footshock during CER training. Data are presented as means 6 SEM. *p,0.05 compared to when
mice received saline control injections.
doi:10.1371/journal.pone.0048665.g002
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(0.01 and 0.032 mg/kg) and i.p. DHbE (3 mg/kg) that were
capable of increasing lever pressing maintained by saccharin
during presentation of an aversive CS also led to a significant
decrease of marble burying in an open, exposed environment.
Repeated measures ANOVA revealed a significant effect of
nicotine exposure on digging behavior as measured by marbles
buried (F2,13 = 4.022, p,0.05). Consistent with results from CER,
post hoc t-tests revealed that mice buried fewer marbles after 0.01
and 0.032 mg/kg i.p. nicotine than when they received saline
(t13=2.747, p,0.05 and t13=2.376, p,0.05, respectively; Fig. 3A).
DHbE-injected mice also buried significantly fewer marbles than
after they received saline vehicle in the marble burying task
(t14=1.781, p,0.05; Fig. 3B).
Antagonism of b2*nAChRs also affected the behavior of mice in
the elevated plus maze. ANOVA analysis revealed a significant
effect of DHbE treatment on latency to reach the terminus of the
open arms (F2,30 = 4.449, p,0.05). Post hoc tests revealed that mice
receiving 0.3 mg/kg i.p. DHbE required significantly less time to
explore the terminal ends of the open arms compared to mice
receiving saline (t17.341 = 2.769, p,0.05; Fig. 4A). Despite similar
trends for DHbE-associated increases in open arm entries and
total time spent in the open arms, ANOVA tests failed to return a
significant effect of treatment for these respective measures
(F2,30 = 2.258, p.0.05; F2,30 = 2.219, p.0.05; Fig. 4), but planned
comparisons revealed that mice receiving 0.3 mg/kg i.p. DHbE
had a significantly greater number of open arm entries than saline-
injected mice (t12.682 = 2.610 p,0.05; Fig. 4B) and spent signifi-
cantly more time in the open arms of the maze compared to saline
controls (t13.490 = 2.753, p,0.05; Fig. 4C). Although there was a
trend for mice receiving 3 mg/kg DHbE to spend more time in
the open arms (t10.992 = 2.034, p=0.068), behavioral measures for
this dose of DHbE failed to reach significance for any behavioral
measure in the elevated plus maze.
To further determine if the observed behavioral effects of
nicotine and DHbE were due in part to non-specific changes in
locomotion, mice were tested in a locomotor activity beam-break
apparatus following administration of saline and doses of nicotine
(0.01 and 0.032 mg/kg) and DHbE (0.3 and 3 mg/kg) that
reversed conditioned suppression in the CER assay, that decreased
digging in the marble burying task, or that increased open arm
activity during the elevated plus maze test. In comparison to
saline-injected animals, there were no observable effects of i.p.
nicotine (F2,14 = 0.072, p.0.05) or DHbE (F2,13 = 1.451, p.0.05)
on locomotor activity (Fig. 5).
Discussion
In the present experiments, low dose nicotine and a selective
antagonist of b2*nAChRs decreased fear- and anxiety-like
behavior in three separate animal models of affect. There was a
significant reversal of conditioned suppression of lever pressing in
mice treated with 0.01 and 0.032 mg/kg i.p. nicotine but a
0.1 mg/kg i.p. dose of nicotine that has been shown to be
rewarding during conditioned place preference [27,28,34] had no
effect. Mice treated with these low doses of nicotine also buried
fewer marbles compared to when they were treated with saline in
an ethological marble burying task, and previous studies show that
similarly low doses of nicotine decrease anxiety-like behavior as
measured by increases in open arm activity in an elevated plus
maze [27,51]. The present findings expand on previous data to
show that inactivation of the high affinity b2*nAChRs has similar
effects of low dose nicotine on these affective tasks. DHbE dose
dependently increased responding for a saccharin reinforcer
during the presentation of an aversive CS, significantly decreased
marble burying in an open, exposed environment and significantly
increased exploration of the open arms of an elevated plus maze.
These divergent behavior-stimulating and behavior-inhibiting
Table 1. Lever pressing activity during the CS and Pre-CS
period.
0.1 mA 0.3 mA
Nicotine (mg/kg) Pre-CS CS Pre-CS CS
Pre-Drug 2.8361.17 1.5060.26 1.6060.40 0.3060.17
0 1.5860.97 1.5060.47 0.8060.40 0.1060.07
0.0032 1.0060.51 1.5060.47 2.0760.11 0.2160.12
0.01 2.8361.38 1.5860.52 1.9060.49 0.4560.16
0.032 4.0061.48 1.5860.97 3.8661.79 0.3660.14
0.1 1.2560.69 1.1760.54 2.2560.68 0.2060.20
DHbE (mg/kg) Pre-CS CS Pre-CS CS
Pre-Drug 2.7561.33 3.9261.48 1.8660.66 0.1460.09
0 1.5860.97 1.5060.47 1.0760.55 0.1460.09
0.1 3.5061.48 2.2560.68 1.2560.36 0.2560.14
0.3 0.7560.34 1.8360.38 1.9360.63 0.1460.09
1 2.8060.88 0.8060.21 2.3660.70 0.5060.29
3 1.7560.48 1.6760.69 2.8661.29 1.7160.79
Lever presses per minute are depicted for mice during presentation of the 60 s
conditioned stimulus (CS) and during the 60 s period prior to CS presentation
(Pre-CS). Pre-Drug levels of responding are depicted for the last day of training
prior to drug testing sessions (Pre-Drug) and during test sessions following each
of five i.p. doses of nicotine or DHbE. Data are represented as means 6 SEM.
doi:10.1371/journal.pone.0048665.t001
Table 2. Lever pressing activity in the absence of the CS.
0.1 mA 0.3 mA
Nicotine (mg/kg) NON-CS NON-CS
Pre Drug 2.6860.95 1.9260.28
0 1.8960.64 0.9460.22*
0.0032 1.3160.48 1.7860.30+
0.01 1.5860.57 1.4060.15
0.032 1.9060.67 2.0960.27+
0.1 1.1060.42 1.3060.18*+
DHbE (mg/kg) NON-CS NON-CS
Pre Drug 3.3360.98 2.8760.49
0 1.8960.64* 1.2160.24*
0.1 1.9860.69 2.3060.41
0.3 2.2160.87 1.8360.30
1 2.4360.72 2.1760.26
3 1.9960.50 2.4160.51
Lever presses per minute are depicted for mice in the absence of the
conditioned stimulus (NON-CS) on the day prior to drug testing sessions (Pre-
Drug) and during test sessions following each of five i.p. doses of nicotine or
DHbE. Data are represented as means 6 SEM; *Significantly different from Pre-
drug training (p,0.05); +Significantly different from test sessions following
saline injection (0 mg/kg; p,0.05).
doi:10.1371/journal.pone.0048665.t002
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measures indicate that these observations were not due to non-
selective effects of DHbE or nicotine on activity. Neither effective
doses of nicotine nor DHbE showed any change in beam break
activity during a locomotor task. Together these findings suggest
that low dose nicotine and DHbE attenuate negative affective and
anxiety-like behavior.
Together with previous findings, these studies identify a dual
role for b2*nAChRs in regulating nicotine reinforcement and
relieving negative affective behavior. Whereas nicotine reinforce-
ment and reward-like behavior require activation of b2*nAChRs
[21–27,29–32,52], the studies described herein suggest that
inactivation of b2*nAChRs decreases fear-like and anxiety-like
behavior as measured by increased suppression ratios during CER,
decreased digging behavior in a marble burying task, and
increased exploratory behavior in the open arms of an elevated
plus maze. Rats will self-administer A-85830, a selective agonist of
b2*nAChRs [52]. Administration of selective b2*nAChR antag-
onists blocks nicotine conditioned place preference and greatly
attenuates nicotine self-administration [21–25]. This is in contrast
to the current studies which show that systemic administration of
DHbE promotes lever pressing maintained by saccharin during
presentation of a stressful cue. The current studies also showed
that subthreshold doses for nicotine conditioned place preference,
but not a reward-like dose, were capable of increasing suppression
ratios during the CER operant task. The non-selective nAChR
antagonist mecamylamine has been shown to have anxiolytic
efficacy in the elevated plus maze, social interaction and marble
burying tasks [53,54,551,56]. The present findings expand on this
work to show that inhibition of b2*nAChRs is sufficient to
decrease fear-like behavior and to increase anxiolytic-like behavior
in Pavlovian/operant and ethological tasks.
Low dose nicotine had similar effects as DHbE to decrease
negative affective behavior. Although the mechanism of how
DHbE and nicotine act at nAChRs has not been clearly elucidated
in an awake, behaving animal, in vitro and ex vivo studies show that
nicotine promotes both activation and desensitization of nAChRs
[17–20,57–59]; hence nicotine-associated desensitization could
result in a behavioral phenotype that is similar to nAChR
antagonism. Micromolar concentrations of nicotine activate
b2*nAChRs, facilitating neurotransmitter release [17–20]. This
is followed by rapid desensitization of the b2*nAChRs [17–20]. In
vitro studies further show that nanomolar concentrations of
nicotine can result in preferential desensitization of b2*nAChRs
[17,57–59]. These studies observed a more robust reversal of
conditioned suppression with DHbE than for low doses of
nicotine. This is likely due to the mixed agonist and desensitizing
properties of nicotine. Unlike complete inactivation of the receptor
as would occur with antagonist binding, at nicotine equilibrium,
nAChRs are thought to be ‘‘smoldering,’’ i.e. capable of
desensitization and activation, depending strongly on nicotine
concentration [57,60]. Low levels of nicotine increase the
likelihood that b2*nAChR stoichiometry will favor the desensi-
tized state. Consistent with these observations, reductions in
marble burying are also observed following administration of
partial agonists of b2*nAChRs, including varenicline and
sazetidine-a [45,54,61,62]. The present data suggest that behav-
ioral effects of partial agonists in the marble burying and CER
tasks are likely due to inhibition rather than activation of the
b2*nAChRs.
It is not clear from these studies which nAChR subunits in
combination with b2 might require inactivation to promote the
anxiolytic-like effects of nicotine. DHbE has high affinity for
a6b2*nAChRs and a4b2*nAChRs [3,63] although a large part of
the sensitivity appears to be driven by the a4 subunit [63]. Recent
work using the elevated plus maze as a measure of anxiety
reported that a4 knockout mice fail to show nicotine-associated
anxiolysis behavior [27]. There was no genotypic effect of the a4
null mutation in the absence of drug, so it is not clear if activation
or inhibition of a4b2*nAChRs or perhaps some other ab*nAChR
is regulating open arm activity in this task [27,64,65]. Selective
deletion of the a4 subunit in ventral tegmental area (VTA)
dopamine (DA) neurons attenuated the effects of nicotine on open
arm entries in the elevated plus maze, suggesting a possible role for
the mesolimbic DA pathway in support of anxiolysis-like behavior
[27]. Given recent data to suggest that VTA GABA neurons
promote conditioned aversion and counter appetitive behavior via
inhibition of DA neuron signaling [66,67], it is possible that
blockade of a4b2*nAChR activity on GABA terminals could
promote anxiolysis-like behavior via disinhibition of DA neurons
[19,20,28]. It is not clear if a6b2*nAChRs, which are enriched in
catecholaminergic nuclei [15,68,69] (but see [70]) might contrib-
ute to anxiety-like behavior. Slice electrophysiology studies show
that a4a6b2*nAChRs on DA neurons in the posterior VTA are
highly sensitive to even nM concentrations of nicotine and are
resistant to desensitization [71] suggesting that their activity, rather
than their inhibition, may promote nicotine-associated anxiolysis
in response to low doses of nicotine. As further support that
desensitization of a4b2*nAChRs promotes anxiolysis-like behav-
ior, the a4b2*nAChRs, but not a6b2*nAChRs, are localized in
the basolateral amygdala where selective removal of ACh inputs
Figure 3. Nicotine and DHbE resulted in fewer marbles buried. A) The 0.01 and 0.032 mg/kg i.p. nicotine that promoted anxiolytic-like
behavior in the CER task also resulted in a significant reduction in digging behavior as measured by fewer marbles buried compared to when mice
were administered saline (n = 14). B) Similarly, mice treated with 3 mg/kg i.p. DHbE also buried less marbles compared to when they received saline
treatment (n = 15). Data are presented as means 6 SEM; *p,0.05 compared to when mice received saline control injections.
doi:10.1371/journal.pone.0048665.g003
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decreases anxiety-like behavior [7,15,68,69,72,73]. A lack of
compounds with selectivity for a6b2*nAChRs that cross the blood
brain barrier make it difficult to assess the stoichiometry of the
b2*nAChRs that support the systemic effects of nicotine; future
studies using selective peptide infusions in brain e.g. [21,22,24] will
help parse the subunit configurations in combination with b2 that
promote anxiolysis via inhibition of b2*nAChRs.
Behaviorally, these nicotine findings are consistent with previous
data. A preponderance of the evidence suggests that low doses of
nicotine promote anxiolysis-like behavior [27,74–76], moderate
doses of nicotine support reward-like behavior [27,28,34], and
high doses of nicotine increase anxiety-like behaviors
[74,75,77,78]. Similarly to low dose nicotine and DHbE,
anxiolytic drugs such as benzodiazepines increase lever pressing
during a presentation of an aversive CS compared to when saline
is administered [35–37,79–83], decrease digging in the marble
burying task [38,42–45] and increase open arm activity in an
elevated plus maze. Studies in humans show that trait anxiety
leads to elevated cued fear conditioning of aversive stimuli and
imaging studies show this behavioral tendency is positively
correlated with an exaggerated activation of the amygdala and
anterior cingulate cortex, brain areas shown to regulate rodent
behavior during fear conditioning tasks [84–89]. CER, marble
burying and the elevated plus maze have good predictive validity
for anxiolytic drug efficacy [35–38,42–47,79–83,90–94]. Together
with previous data, the present studies suggest that inactivation of
nAChRs may promote anxiolysis-like behavior and may have
mechanistic implications for why individuals smoke to relieve
anxiety.
These studies utilized CER, marble-burying and an elevated
plus maze task to show that nicotine and DHbE could both
stimulate and suppress behavior in a way that is consistent with
currently available anxiolytic drugs [38,43–47,90–94]. Marble
burying, however is also sensitive to antidepressant drugs and
antipsychotics [44,48–50] suggesting that digging behavior in
rodents may be driven by an underlying system that is common to
the effects of these diverse drug classes. Individuals diagnosed with
anxiety disorder, depression or schizophrenia all have a signifi-
cantly elevated risk for tobacco dependence [95,96]. In addition to
the high concordance with tobacco use, there is a high
comorbidity for diagnosis of anxiety with depression and
schizophrenia, suggesting that there is a common underlying
etiology for these disorders [97]. Some suggest that the ‘‘non-
purposeful’’ digging behavior in the marble burying task may
model obsessive compulsive anxiety disorder [48–50]. Drugs such
as clozapine, apiprizole and risperidone that are used to augment
the effects of mood stabilizers also reduce marble burying activity
[48,49]. b2*nAChRs are ubiquitously expressed in the brain
[15,68,69,98,99] where their activation on the neuron soma and
terminals promotes release of GABA, serotonin, dopamine,
norepinephrine and acetylcholine, neurotransmitters that regulate
mood and arousal and that are believed to contribute to the
etiology of anxiety, depression and schizophrenia [100]. The
b2*nAChRs have also been implicated in contributing to rodent
models of depression-like behavior with mecamylamine and
partial agonists of b2*nAChRs showing anti-depressant-like
efficacy [101–103]. Unlike our observations in the marble burying
task, however, administration of DHbE blocks the antidepressant-
like effects of the b2*nAChR partial agonists varenicline and
sazetidine in the forced swim task [104], showing a dichotomy
Figure 4. Antagonism of b2*nAChRs promoted anxiolysis-like
behavior in the elevated plus maze. A) Mice receiving 0.3 mg/kg
i.p. DHbE required less time to explore the end terminus of the open
arms of an elevated plus maze, B) made more entries into the open
arms of the maze and C) spent more time in the open arms than saline-
injected mice. Data are presented as means 6 SEM; *p,0.05,
#p= 0.067 compared to saline controls.
doi:10.1371/journal.pone.0048665.g004
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with the present results in the elevated plus maze which suggest
that antagonism of b2*nAChRs promotes anxiolysis-like behavior.
It is possible that our findings in the CER task reflect changes in
learning that are independent of fear and anxiety-like behavior.
While it is possible that drug injection could result in state-
dependent learning effects, we do not believe this was the case
given that animals showed dose-dependent effects of nicotine and
DHbE using a within-subject, Latin Square design. Place
conditioning and drug discrimination studies clearly demonstrate
that mice can physiologically detect the 0.1 mg/kg dose of nicotine
[27,28,34,105–108] yet this dose did not reverse conditioned
suppression as low doses did in these studies, suggesting that the
effects of nicotine and DHbE on suppression ratios during CER
were not due to a generalized decrement caused by state-
dependent learning. It is also possible that the injection itself
could have served as an occasion-setter to indicate that no shock
would occur during these test sessions. This was not the case.
Rather, saline injection led to a decrease in NON-CS responding
during these test sessions, suggesting that the stress of injection led
to a reduction in goal-oriented behavior as measured by lever
pressing for saccharin. Several doses of nicotine, including a
rewarding-like dose, reversed this suppression of NON-CS
responding. Whereas it is possible that this behavior was
stimulated by anxiolytic-like effects of nicotine, it is equally
plausible that nicotine exposure promoted stimulus enhancing
effects of the saccharin reinforcer as has been shown for an
unconditioned stimulus light and a conditioned stimulus associated
with an appetitive stimulus [40,41,109,110]. The present results
also showed an interesting contrast to findings using Pavlovian fear
conditioning without an operant component. Unlike our observa-
tions in the CER task, systemic administration of nicotine
enhances freezing in a footshock-paired context with no effect
on explicit cue conditioning [111,112]. These dichotomies may be
due in part to the use of a more mild footshock and extended
explicit cue CS training used during CER compared to traditional
Pavlovian fear conditioning procedures. A significant difference in
CS but not NON-CS lever pressing between mice trained to a
0.1 mA and 0.3 mA footshock suggests that the contextual fear did
not contribute to CER behavior in these studies. In addition,
systemic administration of DHbE alone does not affect either
context or explicit cue CS-freezing following fear conditioning
[113], drawing a further contrast between these procedures.
Together these findings suggest that basic Pavlovian fear
conditioning and CER are modeling different behaviors. These
data further suggest that CER, but not Pavlovian fear condition-
ing, is sensitive to inactivation of the high affinity b2*nAChRs.
Whereas the CER paradigm is a complex animal model that
involves fear learning and operant behavior, this procedure
benefits from subjects acting as their own controls both within
and between sessions. The fact that mice showed similar effects in
the marble-burying task and elevated plus maze, which do not
have a learning components to them, supports the hypothesis that
affective behavior was modified by nicotine and DHbE during
CER.
Studies in human smokers reveal that multiple factors contrib-
ute to tobacco use; as well as the pleasure received from smoking,
many report that they use tobacco to relieve anxiety or to relax
[114–120]. The first cigarette of the day results in an abrupt
increase in nicotine plasma concentrations that smokers associate
with the rewarding effects of the drug [121–123]. The nicotine
ingested from a single cigarette is sufficient to occupy 80% of
b2*nAChRs [124]. During subsequent smoking episodes, smokers
achieve smaller increases in nicotine that ought to preferentially
favor desensitization of nAChRs [121,122] if slice electrophysiol-
ogy, Xenopus oocyte, tissue culture and synaptosome studies are
predictive of how nAChRs function in vivo [17–20,57–59].
Nicotine reaches daily steady-state concentrations in the brains
of human smokers between 200–400 nM. ACh is a major
neuromodulator in brain that is thought to regulate anxiety-like
behavior [73,125]. As nicotine levels drop, populations of
b2*nAChRs in brain regions that regulate anxiety become
available for activation by ACh in response to stressful stimuli
such as cigarette/tobacco cues [126–129]. Hence, in addition to
smoking to activate their b2*nAChRs, tobacco users may also be
titrating ACh signals via desensitization of the b2*nAChRs,
particularly after the first cigarette of the day. Human imaging
studies suggest that b2*nAChRs may be critical for nicotine’s
ability to curb anxiety in smokers [130,131] but presently available
compounds that assess b2*nAChR occupancy in humans cannot
differentiate between receptors in the activated or desensitized
state.
To conclude, low dose nicotine and DHbE had similar effects
on affective behavior in the CER, marble burying and elevated
plus maze tasks. These studies support the hypothesis that nicotine
may reduce negative affect and anxiety via desensitization of the
high affinity b2*nAChRs. These data further suggest that
antagonism of b2*nAChRs may be an effective strategy for
promoting tobacco cessation or for relieving anxiety in non-
tobacco users.
Figure 5. Nicotine and DHbE did not affect locomotor activity. Doses of A) nicotine (n = 526) and B) DHbE (n = 425 per group) that promoted
anxiolytic-like behavior in the CER and marble burying tasks did not affect locomotor activity as measured by beam breaks (Fs = 0.072, 1.451,
ps.0.05). Data are presented as means 6 SEM.
doi:10.1371/journal.pone.0048665.g005
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Supporting Information
Figure S1 Operant responding during individual ses-
sions in absence of drug. Variability in Pre-CS responding
was observed in mice exposed to both 0.1 and 0.3 mA footshock
unconditioned stimulus (US) over within-subject delivery of both
nicotine and DHbE. The timing of the conditioned stimulus (CS)
may have contributed to this variability, as operant responding
fluctuated within individual sessions.
(DOCX)
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